Nusinersen is the first FDA-approved drug for SMA, which is an antisense oligonucleotide-based compound targeting the intronic splicing silencer and thereby regulating the splicing of SMN2 exon 7 [46]. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.